Bispecifics in R/R MM: Unanswered Questions
Panelists discuss how despite the significant progress with bispecifics in relapsed/refractory multiple myeloma (R/R MM), major unanswered questions remain including optimal sequencing strategies (which represent the biggest challenge), how to implement bispecifics earlier in the treatment paradigm, and how to integrate them with other existing therapies in the evolving treatment landscape.
EP: 1.MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data
EP: 2.MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data (Part 2)
EP: 3.Data Review of Teclistamab and Elranatamab in R/R MM
EP: 4.Expert Opinion on Modern Availability of Several Agents
EP: 5.Future of R/R MM: Emerging Bispecifics and Trispecifics
EP: 6.Optimal Dosing of Talquetamab
EP: 7.Optimal Dosing of Talquetamab (Part 2)
EP: 8.Talquetamab: Real-World Outcomes With Outpatient Dosing
EP: 9.Teclistamab: OPTEC Trial Overview
EP: 10.MonumenTAL-1: Safety Outcomes
EP: 11.Optimal Sequencing Strategies With Bispecifics in R/R MM
EP: 12.Bispecifics in R/R MM: Unanswered Questions
Bispecifics in R/R MM: Unanswered Questions
Despite significant advances in bispecific antibody therapy for R/R MM, several critical questions remain unanswered. The most pressing unmet need continues to be optimal sequencing strategies, representing the biggest challenge facing clinicians as the therapeutic landscape becomes increasingly complex. As multiple bispecific agents become available across different targets, determining the most effective order of administration and identifying the optimal timing for each therapy requires further investigation through clinical experience and formal studies.
The next major frontier involves the earlier implementation of bispecific antibodies in the treatment paradigm. Questions remain about how to integrate these highly effective therapies into earlier lines of treatment and how this earlier use will impact the sequencing and effectiveness of other available therapies. This shift toward earlier implementation could potentially reshape the entire treatment approach for multiple myeloma but requires careful study to understand long-term implications and optimal combinations.
Additional lingering questions include the development of combination strategies, duration of therapy considerations, and strategies for overcoming resistance mechanisms. As the field moves toward earlier use of bispecifics, understanding how traditional therapies will fit into the new treatment landscape becomes increasingly important. The hope is that ongoing clinical trials, real-world evidence collection, and collaborative efforts will provide answers to these fundamental questions, leading to improved patient outcomes and more rational therapeutic approaches in multiple myeloma care.
